Human Chorionic Gonadotropin Market Size & Share, by Application (Fertility Treatment, Hypogonadism Therapy, Other Therapeutic Uses); End user; Product type - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2034

Human Chorionic Gonadotropin Market - Regional Analysis

North America Market Insights

North America is set to dominate the global human chorionic gonadotropin  HCG market with the largest share of 42.6% by the end of 2034. The heightened administrative support and reimbursement expansions are key factors reinforcing the region’s dominance in this sector. Besides, the U.S. fuels 90.6% of regional demand, whereas Canada supports this growth with strong funding allocations. In addition, the U.S. FDA fast-tracked approvals for the advanced HCG dosing tools, which have reduced the treatment cycles by improving cost-efficiency. Furthermore, the existence of huge private insurers also propels a profitable business environment in the region.

The U.S. is augmenting its dominance in the regional HCG market on account of suitable and profitable reimbursement policies. In this regard, the CMS data states that Medicare in 2024 expanded its coverage for recombinant HCG in obesity related infertility. Besides, HCG is preferred by wider healthcare settings owing to its extended shelf life, which reduces waste by 20.6% in clinics in the country.  On the other hand, the telemedicine integrated fertility platforms, such as Progyny, demonstrated a 35.6% increase in prescriptions through remote monitoring, thus denoting the presence of a strong consumer base.

Canada is also portraying steady growth in North America’s human chorionic gonadotropin (HCG) market, successfully led by strong administrative provinces.  As evidence, Ontario assigned USD 420.6 million to fertility clinics.  Meanwhile, Health Canada concentrates on affordable urinary HCG, enabling coverage to 70.8% of treatments as stated in the Canadian Institute for Health Information (CIHI). Furthermore, the country has been witnessing considerable gaps in the rural areas, wherein 40.6% of ART clinics are present in the urban areas as of the Public Health Agency of Canada's 2023 report.

APAC Market Insights

Asia Pacific is likely to exhibit the fastest growth in the HCG market from 2025 to 2034. This accelerated upliftment in the region is a result of rising infertility rates, government-funded fertility programs, and technological advancements as well. The landscape is deliberately led by Japan due to the presence of AI-based HCG therapies with substantial funding granted from MHLW for long-acting formulations. This dominance is closely followed by China, India, South Korea, and Malaysia, wherein Malaysia emphasizes 20.6% budget hikes with a prime focus on fertility clinic upgrades.

China is gaining enhanced traction in the regional human chorionic gonadotropin (HCG) market owing to the existence of massive government investments and domestic manufacturing capabilities. In this regard, the National Medical Products Administration (NMPA) in 2023 stated that it cleared the approvals of 8 new recombinant HCG drugs, thereby capturing an estimated 60.6% share in the domestic market. Furthermore, the NHFPC stated that the country received a total of USD 7.2 billion under the Healthy China 2030 initiative to modernize fertility clinics, targeting 90.7% 4k and 8k HCG adoption in tier 3 hospitals by the end of 2027, hence a wider market scope.

India is also demonstrating lucrative progress in the human chorionic gonadotropin market with supportive government policies and domestic production initiatives. In this regard, the Ministry of Health and Family Welfare notes that the Ayushman Bharat scheme subsidized urinary HCG for 6.7 million patients, reflecting a strong fiscal backup for underprivileged areas. Besides, the government spending surpassed USD 2.2 billion in 2023, marking an 18.5% since the last decade. On the other hand, organizational collaborations are yet another asset for this landscape, with AIIMS’s partnering with Olympus reducing recombinant HCG costs by 35.8% through domestic production.

Country-wise Government Provinces

Sources: AMED, Health.gov.au, K-FDA, MOH

Europe Market Insights

Europe in the human chorionic gonadotropin (HCG) market is significantly growing with a share of 28.5% during the discussed timeframe. The growth in the region is subject to regulatory harmonization and rising infertility rates. Besides, the European Medicines Agency (EMA) states that its 2024 guidelines prioritize recombinant HCG, which allowed it to capture 65.7% of the region’s demand. Simultaneously, the European Health Data Space assigned €2.7 billion for fertility research, including HCG innovation, thus making it suitable for standard market growth.

Germany is showcasing its policy-driven growth in the HCG market with an 18.8% regional revenue share. The strategic public funding grants and strong manufacturing capabilities, producing 40.8% of the region's recombinant HCG raw materials, also foster a profitable business environment in the country. In this regard, the Federal Ministry of Health (BMG) in 2024 allocated a total of €220.8 million to AI-optimized fertility treatments, thereby enabling coverage to 30.7% of HCG cycles through its Digital Healthcare Act.  This, in turn, reduced the treatment expenses by 20.5% by improving IVF success rates by a significant 15.5%.

France in the human chorionic gonadotropin market is growing at a rapid pace owing to the presence of government-backed innovation and expanded healthcare access. As evidence, the National Authority of Health (HAS) states that it mandated recombinant HCG as the standard for public hospitals in 24.5% fueling the increased adoption. Besides, the country also received €300.8 public-private funding, which has significantly accelerated the development of self-injection HCG devices, with Ferring Pharmaceuticals launching the first-ever EMA-approved pen called FertilePen in 2023.  Moreover, the country leads in terms of long-acting HCG formulations, which are predicted to capture 35.4% of the market by the end of 2027.

Government Investments, Policies & Funding

Sources: NHS England, Italian Government, Ministry of Health